Clinical trials: Brain and Central Nervous System Tumors
Blood Pressure, Depression
Essential Hypotension and Allostasis Registry
The essential arterial hypotension and allostasis registry is a prospective, observational research that has the purpose of demonstrating that essential blood pressure (BP) disorders and the associated comorbidities are a result…
- Conditions
- Blood Pressure, Depression, Panic Attack, Fibromyalgia
- Trial name
- ESSENTIAL (NCT02018497)
- Where
- Colombia
- Volunteers
- 5,000 people
- Sponsor
- CES University
Brain and Central Nervous System Tumors
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide and carmustine, work in different ways to stop tumor cells from dividing…
- Trial name
- NCT00086879
- Testing
- carmustine, erlotinib hydrochloride, temozolomide
- Where
- 10 sites in Belgium, France and 3 more
- Volunteers
- 110 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Childhood Brain Tumor
International HIT-MED Registry (I-HIT-MED)
The I-HIT-MED registry registers clinical of children and adults with medulloblastoma, ependymoma, pineal tumours, or choroid plexus tumours in Germany and other countries that fulfil national ethic requirements for participation…
- Trial name
- NCT02417324
- Where
- 57 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Low Grade Gliomas, Craniopharyngioma
SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors
Brain tumours are the commonest solid tumours in children and the second most common neoplasms overall in this patient population. Radiotherapy plays an important part in the management in a majority of these tumours.
- Conditions
- Low Grade Gliomas, Craniopharyngioma, Ependymomas, Meningiomas
- Trial name
- SCRT (NCT00517959)
- Testing
- Stereotactic Conformal radiotherapy, Conventional radiotherapy
- Where
- India
- Volunteers
- 200 people
- Sponsor
- Tata Memorial Hospital
Glioblastoma, Gliosarcoma, Adult
A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.
WinGlio is a phase I study investigating neoadjuvant (before surgery) ipilimumab ( a type of immunotherapy drug) in patients with newly diagnosed glioblastoma (a form of brain cancer).
- Conditions
- Glioblastoma, Gliosarcoma, Adult, Glioblastoma - Category
- Trial name
- WinGlio-ipi (NCT07134842)
- Testing
- Ipilimumab (3 mg/kg)
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- University College, London
Glioblastoma, Anaplastic Astrocytoma
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
In this multinational dose finding Phase IIb study the efficacy and safety of two doses of AP 12009 compared to standard chemotherapy (temozolomide or PCV) is investigated in adult patients with confirmed recurrent high-grade…
- Trial name
- NCT00431561
- Testing
- AP 12009 10 µM, AP 12009 80 µM, temozolomide or PCV
- Where
- 36 sites in Austria, Georgia and 4 more
- Volunteers
- 141 people
- Sponsor
- Isarna Therapeutics GmbH
Brain Metastases, HR+ Metastatic Breast Cancer
SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases
This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases.
- Trial name
- NCT04923542
- Testing
- Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Brain Metastases, Primary Brain Tumors
Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors
Sorafenib™ has the potential to inhibit tumor growth, tumor angiogenesis , and enhance radiation response. This study will test the combination of Sorafenib™ and radiation therapy with or without temozolomide to determine…
- Trial name
- NCT00639262
- Testing
- Sorafenib, Temozolomide, Radiotherapy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4
IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas
STAR-VACC is a randomized double-blind controlled Phase 2 study assessing clinical efficacy of IDH1-vac in patients with newly diagnosed IDH1-mutant high-grade astrocytomas.
- Trial name
- STAR-VACC (NCT07888647)
- Testing
- IDH1-vac, IS-vac, Temozolomide (TMZ)
- Where
- 13 sites in Germany
- Volunteers
- 216 people
- Sponsor
- German Cancer Research Center
Adrenal Cortical Cancer, Brain Cancer
Spectroscopy With Surface Coils and Decoupling
The purpose of this study is to obtain chemical information from part of your body without a biopsy. This is done using a technique called magnetic resonance spectroscopy (MRS) which is similar to magnetic resonance imaging (MRI)…
- Conditions
- Adrenal Cortical Cancer, Brain Cancer, Breast Cancer, CNS Cancer
- Trial name
- NCT00581815
- Testing
- Proton-decoupled 31P MRS at 1.5T, 1H Spectroscopy at 1.5T and 3T
- Where
- United States
- Volunteers
- 582 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Neoplasms
Improving Surgical Outcomes in Patients With Low Grade Gliomas Using Advanced Pre- and Intra-operative MRI
This aim of this study is to improve the outcomes for patient with gliomas undergoing neurosurgery by maximising the extent of resection whilst minimising neurological morbidity.
- Trial name
- NCT02884947
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- University College, London
DIPG Brain Tumor, Diffuse Brainstem Glioma
Single Patient Compassionate Use / Expanded Access L-S-Gboxin (Lyophilized Form of S-Gboxin) for the Treatment of Diffuse Midline Glioma
F. 50y.o. 77kg, DS confirmed 18 Nov. 2022 Received treatment: 11 courses of TMZ (240mg) Radiotherapy 30 courses of 1.8Gr (total 54 Gr, TMZ 140 mg on RT). Bevacizumab intravenously -400 mg -0-14-28-42 (December-February 2023).
- Conditions
- DIPG Brain Tumor, Diffuse Brainstem Glioma, H3 K27M, H3 K28M
- Trial name
- TRIANGLE (NCT06439849)
- Testing
- S-Gboxin
- Sponsor
- Petrov, Andrey
Brain Tumors
Frailty as a Predictor of Neurosurgical Outcomes in Brain Tumor Patients
Frailty as an adjunct to preoperative assessment of neurosurgical patients has never been evaluated. This study aims to determine if frailty predicts neurosurgical complications in brain tumor patients and enhances current…
- Trial name
- NCT02530749
- Where
- United States
- Volunteers
- 265 people
- Sponsor
- University of Colorado, Denver
Head and Neck Squamous Cell Carcinoma, Brain Metastases
Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.
- Trial name
- NCT05996432
- Testing
- Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), 18F-fluoromisonidazole
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
RECURRENT GLIOBLASTOMA, Brain Tumor
Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)
This protocol is designed to generate and provide preliminary data to determine the safety and activity of combination therapy using tumor treating fields (TTFields; Optune(NovoTTF-100A); Novocure, Haifa, Israel), a novel…
- Trial name
- NCT01925573
- Testing
- Optune(NOVOTTF-100A)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Maryland, Baltimore
Metastatic Colorectal Cancer
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)
The purpose of this study is to determine safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) for the following combinations: pembrolizumab plus binimetinib (Cohort A), pembrolizumab plus…
- Trial name
- NCT03374254
- Testing
- Pembrolizumab, Binimetinib, Oxaliplatin
- Where
- 14 sites in United States, Canada
- Volunteers
- 116 people
- Sponsor
- Merck Sharp & Dohme LLC
Low Grade Glioma of Brain, Glioblastoma
Feasibility of the LUM Imaging System for Detection of Cancer to the Brain
The overall objective of this study is to assess the safety and efficacy of the LUM Imaging System in imaging primary and metastatic cancer in the brain.
- Conditions
- Low Grade Glioma of Brain, Glioblastoma, Metastasis to Brain
- Trial name
- NCT03717142
- Testing
- LUM Imaging System
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Lumicell, Inc.
Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after…
- Trial name
- STELLAR (NCT02796261)
- Testing
- Eflornithine, Lomustine
- Where
- 79 sites in United States, Belgium and 6 more
- Volunteers
- 343 people
- Sponsor
- Orbus Therapeutics, Inc.
Pituitary Adenoma Invasive, Nasal Obstruction
Nasal Obstruction Compared by Rhinomanometry and Nasal Inspiratory Peak Flow After Endoscopic Nasal Surgery
The aim of the project is to determine whether nasal inspiratory peak flow is sufficient for preoperative and postoperative measurement of nasal patency compared to rhinomanometry.
- Trial name
- NCT05921396
- Testing
- Nasal patency - rhinomanometry, Nasal patency - nasal inspiratory peak flow
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- University Hospital Ostrava
Brain Neoplasms
Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases
Phase 1, Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases.
- Trial name
- NCT00393965
- Testing
- MPC-6827
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Myrexis Inc.